GSK acquires from Chimagen Biosciences CMG 1A46 a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE)

For over a decade, GSK has been a pioneer in the treatment of lupus. This agreement underscores the importance of novel therapeutic approaches to address the heterogeneity of lupus manifestations and the continued burden, particularly in patients who suffer from severe disease and are refractory to current standard of care.

Tony Wood, Chief Scientific Officer, GSK, said: “Through our work in systemic lupus erythematosus and lupus nephritis, we increasingly understand the underlying drivers of B cell-driven diseases. As a novel therapeutic option directed at deep B cell depletion, CMG 1A46 offers exciting potential which we are pleased to take forward to address unmet need in lupus and related autoimmune conditions.”

CD20 is an established target in the treatment of autoimmune diseases and there is growing clinical evidence that CD19 shows promise as a differentiated therapeutic approach given its presence on more B cell types. In preclinical studies, CMG 1A46, designed to target both CD19 and CD20, has shown rapid, deep B cell depletion both in the bloodstream and in tissues which could lead to more durable responses in patients.

Under the terms of this agreement, GSK will pay $300 million upfront to acquire full global rights to CMG 1A46. In addition, Chimagen will be eligible to receive success-based development and commercial milestone payments for CMG 1A46 totalling $550 million. This agreement is subject to customary conditions, including applicable regulatory agency clearances under the Hart-Scott-Rodino Act in the US.